Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01490749 · ClinicalTrials.gov registry record · Phase 1

Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

A Phase 1 study of Esophageal Cancer and Neoplasms, Esophageal, sponsored by Emory University.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target
3
Study locations

NCT01490749 is a Phase 1 study of Esophageal Cancer and Neoplasms, Esophageal that has completed, run by Emory University. The registered enrollment target is 17 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01490749, a Phase 1 study of Esophageal Cancer and Neoplasms, Esophageal, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to test the drug RAD001 in combination with another chemotherapy drug, Carboplatin, as well as radiation therapy in the treatment of esophageal cancer. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combination. The standard of care for patients who have esophageal cancer that has not moved to other areas of the body (non-metastatic) includes a combination of chemotherapy, radiation therapy and possibly surgery. If the patient chooses to participate in this study, the patient will receive chemotherapy and radiation therapy. The patient will possibly also have surgery to have the cancer removed. This decision will be made by the treating physicians. All of the chemotherapy the patient will receive on the study is considered standard chemotherapy for esophagus cancer. The investigators do not know as of yet if the drug called RAD001 will help improve the treatment for patients with this disease. RAD001 is a pill that has been used in many other types of cancer and has been proven to be effective in other cancers such as kidney cancer.

Conditions Studied

Esophageal Cancer Neoplasms, Esophageal

Interventions

  • DRUG Carboplatin
  • RADIATION Radiation
  • DRUG XELOX
  • DRUG RAD001

Study Locations (3)

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Winship Cancer Institute - Atlanta

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2012-02
Est. Completion 2019-02
Phase Phase 1

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01490749

The ClinicalTrials.gov registry entry for NCT01490749 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT01490749 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Tennessee.

Frequently Asked Questions

What is clinical trial NCT01490749 about?

NCT01490749 is a clinical study titled "Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer". The purpose of this study is to test the drug RAD001 in combination with another chemotherapy drug, Carboplatin, as well as radiation therapy in the treatment of esophageal cancer. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combi...

What is the current status of trial NCT01490749?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2012-02. Estimated completion is 2019-02.

What conditions does trial NCT01490749 study?

This clinical trial studies the following conditions: Esophageal Cancer, Neoplasms, Esophageal.

What interventions are being tested in trial NCT01490749?

The interventions under investigation include: Carboplatin (DRUG), Radiation (RADIATION), XELOX (DRUG), RAD001 (DRUG).

Who is sponsoring clinical trial NCT01490749?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01490749 being conducted?

This trial has 3 study locations across Georgia, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Esophageal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Esophageal Cancer

All registered trials for this condition

Neoplasms, Esophageal

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.